Stock Quote
POZEN Inc. (POZN.W) (NASD ADF)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View POZN on other exchanges
$7.17
10:24am EST
+8.31%
$6.62
$7.17
100
$7.17
$7.17
$8.42
$4.50
1.22
111,940
POZN.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Plachetka, John | Chairman of the Board, President, Chief Executive Officer | 2,244,440 |
| Hodges, William | Chief Financial Officer, Senior Vice President - Finance and Administration | 1,053,190 |
| Cermak, Elizabeth | Executive Vice President, Chief Commercial Officer | -- |
Profile
POZEN Inc. (POZEN), is a pharmaceutical company focused on developing products, which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain, and pain related conditions. The Company has developed Treximet (formerly known as Trexima) in collaboration... Full Description
Company Address
POZEN Inc.
1414 Raleigh Road
Suite 400
Chapel Hill NC 27517
P: +1919.9131030
F: +1919.4905552
1414 Raleigh Road
Suite 400
Chapel Hill NC 27517
P: +1919.9131030
F: +1919.4905552
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| Merck & Co., Inc. | $36.42 | -0.04 |
| AstraZeneca plc | £2,732.00 | +37.00 |
| POZN.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 3.57 |
| P/S(TTM) | 4.94 | 0.57 |
| ROI(TTM) | -12.02 | 1.86 |
| ROE(TTM) | -13.56 | 2.51 |
| Consensus Recommendation | Hold |
|---|---|
| EPS Est. (Current Period) | -0.13 |
| EPS Est. (Current Year) | -0.22 |
| Total Revenue | $14.29M |
| Net Income | $6.66M |
| EPS | $0.22 |
